Halted trial tests new hope for lymphoma patients Who've run out of options
NCT ID NCT04486391
Summary
This study aimed to test whether a new immunotherapy drug called tislelizumab works better than standard chemotherapy for people with Hodgkin lymphoma that has returned or stopped responding to previous treatments. The trial was designed to enroll many patients but was stopped early after only 3 people joined. Researchers wanted to see if the new drug could help patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Quanzhou First Affliated Hospital of Fujian Medical University
Quanzhou, Fujian, 362000, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.